April 21, Tianjin Northnet News: After  ≥σmore than half a year of demonφ★φstration in the Tianjin Pilot Free T∏•♠©rade Zone, the "Report on the Pilot Tλ←εest of Cell Therapy in the Tianjin Ω♣✔★Pilot Free Trade Zone" was d<'≤©rafted and then submit∞•☆™ted to the Ministry of£≥π Commerce of the People’s R≠± epublic of China, and the Municipal♦™£® Health The health, drug¥∑♣∏ supervision, and tech✘δnology departments jointly±≠₩ organize industry regulatory organiza ↓♠₽tions to promote the adm≠←ission of low- and medium-r•&<isk cell therapy prodβ>÷ucts with medical technology and car£•∞≤ry out clinical applicatio>"βns. Patients with reΩ✔<δlated diseases can directly eα♦↕njoy cell diagnosis and treatment in ∑®♣>the Tianjin Pilot Free Trade Zone and☆☆₩& the Joint Innovation Zone. Sci←'entific research insti©∏♦tutions and cell technology-¥≥€§related companies ca☆‌n also let go of research ™♣₹and realize clinical translation∞‍λal applications more quicklλ↑y. Joint Power Biotechnology Co., Ltdλ₽., a subsidiary of Tianjin Anda G&←₽roup, firmly seized the opportuni© ∑ty to focus on the world's leadiΩ¥♦↑ng technology in the ×™ regeneration and repair of au✔πλ→tologous cartilage cells. α→The District Bureau o∏↑∞f Science and Industry es"×≥‍tablished contacts, introdu☆₹☆<ced the company's deve∏₩lopment history, provided detailed t  αechnical materials for→"™♦ the project, and invited them∏∞‍α to the company for inspecti$÷♦on and guidance.